Enginprime Medical Raises $12 Million Series A to Advance OpusOne Heart Support Device Globally

The company will use the new funding to support the clinical trial registration of its OpusOne™ device in China. The money will also help with regulatory submissions and early clinical development of the technology in global markets.

"We are deeply grateful to Qiming Venture Partners and Voyagers Capital for their strategic support," said Zhiyong Liu, Chief Executive Officer of Enginprime. "This funding marks a pivotal milestone as we advance and scale a globally competitive pVAD system. We are committed to executing our global clinical and regulatory strategies to deliver reliable, cost-effective percutaneous ventricular assist solutions to market."

Shuo Mao, Principal of Qiming Venture Partners said, " The foldable impeller pVAD achieves greater flow capacity with a lower-profile design, effectively reducing clinical complications and broadening patient eligibility and clinical applicability. It delivers significant clinical value for ventricular assist therapy. To date, no comparable product has obtained global regulatory approval, representing an untapped technological frontier in the industry. We believe that with solid industrial expertise and profound clinical insights, coupled with the joint efforts of its core team and shareholders, Enginprime's differentiated pVAD innovation is poised to fill the global market gap and bring substantial therapeutic benefits to patients worldwide."

"Enginprime came out of Voyagers Capital's Venture Creation model, and the team has more than delivered on the bar we set when we started the company," said Fiona Zhang, Partner at Voyagers Capital. "We see a clear gap and opportunities in the global pVAD market, and look forward to bringing OpusOne™ to the market in China and globally with the support of Qiming Venture Partners and other strategic partners."

Founded in 2023 by Voyagers Capital and led by CEO Zhiyong Liu, Enginprime Medical is a medical device company developing advanced percutaneous ventricular assist devices (pVADs) to support heart function.

The company’s main product is OpusOne, a pVAD designed to provide higher blood flow while using a smaller catheter. It uses a foldable impeller design, which allows the device to be delivered through a smaller access point.